Equities research analysts expect Aduro BioTech Inc (NASDAQ:ADRO) to report earnings of ($0.21) per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Aduro BioTech’s earnings, with estimates ranging from ($0.23) to ($0.18). Aduro BioTech reported earnings per share of ($0.28) during the same quarter last year, which would suggest a positive year-over-year growth rate of 25%. The company is scheduled to report its next earnings results on Wednesday, February 26th.
According to Zacks, analysts expect that Aduro BioTech will report full year earnings of ($0.99) per share for the current year, with EPS estimates ranging from ($1.02) to ($0.89). For the next year, analysts anticipate that the business will post earnings of ($0.79) per share, with EPS estimates ranging from ($1.02) to ($0.41). Zacks Investment Research’s EPS averages are an average based on a survey of analysts that cover Aduro BioTech.
Aduro BioTech (NASDAQ:ADRO) last announced its earnings results on Thursday, November 7th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.03. The business had revenue of $4.80 million for the quarter, compared to analysts’ expectations of $4.55 million. Aduro BioTech had a negative return on equity of 78.64% and a negative net margin of 544.94%.
NASDAQ ADRO traded down $0.01 during midday trading on Friday, hitting $1.09. 349,300 shares of the company traded hands, compared to its average volume of 567,054. The company has a debt-to-equity ratio of 0.39, a current ratio of 7.26 and a quick ratio of 7.26. The company has a market cap of $90.98 million, a PE ratio of -0.94 and a beta of 1.48. The company’s 50-day simple moving average is $1.04 and its 200-day simple moving average is $1.72. Aduro BioTech has a 52 week low of $0.90 and a 52 week high of $4.59.
In other news, CEO Stephen T. Isaacs sold 31,098 shares of the firm’s stock in a transaction on Friday, September 13th. The stock was sold at an average price of $1.31, for a total value of $40,738.38. Following the completion of the sale, the chief executive officer now owns 295,926 shares of the company’s stock, valued at approximately $387,663.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 52,185 shares of company stock valued at $68,362 in the last three months. Insiders own 5.20% of the company’s stock.
Institutional investors have recently bought and sold shares of the company. Baillie Gifford & Co. boosted its position in shares of Aduro BioTech by 6.2% in the 2nd quarter. Baillie Gifford & Co. now owns 4,070,724 shares of the biotechnology company’s stock worth $6,269,000 after purchasing an additional 239,298 shares in the last quarter. DekaBank Deutsche Girozentrale raised its stake in Aduro BioTech by 63.6% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 58,400 shares of the biotechnology company’s stock worth $102,000 after acquiring an additional 22,700 shares during the last quarter. JPMorgan Chase & Co. raised its stake in Aduro BioTech by 196.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,414,065 shares of the biotechnology company’s stock worth $2,474,000 after acquiring an additional 937,166 shares during the last quarter. Northern Trust Corp raised its stake in Aduro BioTech by 1.6% in the 2nd quarter. Northern Trust Corp now owns 759,916 shares of the biotechnology company’s stock worth $1,171,000 after acquiring an additional 12,133 shares during the last quarter. Finally, Alambic Investment Management L.P. purchased a new position in Aduro BioTech in the 2nd quarter worth $62,000. 41.24% of the stock is owned by hedge funds and other institutional investors.
About Aduro BioTech
Aduro BioTech, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies to harness the body's natural immune system for the treatment of patients with challenging diseases. The company is developing ADU-S100, which is in Phase I dose escalation and dose expansion clinical trial and Phase Ib dose escalation and dose expansion clinical trial in combination with spartalizumab to treat patients with advanced, metastatic treatment-refractory solid tumors; Phase I clinical trial in combination with ipilimumab for the treatment of relapsed and refractory melanoma; and Phase Ib/II clinical trial in combination with an approved anti-PD-1 antibody in patients with squamous cell carcinoma of the head and neck.
Read More: What Factors Can Affect Return on Equity?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.